国药股份(600511) - 2023 Q3 - 季度财报

Financial Performance - Q3 2023 revenue was approximately ¥12.39 billion, a decrease of 1.17% year-over-year, while year-to-date revenue reached approximately ¥36.53 billion, an increase of 5.75%[3] - Net profit attributable to shareholders for Q3 2023 was approximately ¥477.71 million, down 16.10% year-over-year, with year-to-date net profit at approximately ¥1.46 billion, an increase of 2.14%[3] - Basic earnings per share for Q3 2023 was ¥0.6332, a decrease of 16.10% year-over-year, while year-to-date basic earnings per share was ¥1.9381, an increase of 2.14%[4] - Net profit for Q3 2023 was ¥1,581,910,864.84, compared to ¥1,544,715,892.67 in Q3 2022, reflecting a growth of approximately 2.4%[16] - Earnings per share for Q3 2023 were ¥1.9381, an increase from ¥1.8974 in Q3 2022, showing a rise of about 2.1%[17] - The total comprehensive income for the third quarter was ¥1,173,212,437.75, compared to ¥1,133,700,683.24 in the same period last year[26] Assets and Liabilities - Total assets at the end of Q3 2023 were approximately ¥31.63 billion, an increase of 6.83% compared to the end of the previous year[4] - The total liabilities decreased to ¥20,000,000,000 from ¥20,500,000,000, indicating a reduction of about 2.44%[12] - The total liabilities as of Q3 2023 amounted to ¥14,828,248,247.38, compared to ¥13,749,571,981.97 in the previous year, marking an increase of approximately 7.8%[14] - The total liabilities amounted to ¥9,678,930,924.61, a decrease from ¥10,069,654,647.71 in the previous year[23] - The total assets as of Q3 2023 were ¥31,631,632,101.15, compared to ¥29,609,041,999.59 in the previous year, indicating an increase of approximately 6.8%[14] Shareholders' Equity - Shareholders' equity attributable to shareholders at the end of Q3 2023 was approximately ¥15.09 billion, an increase of 6.14% compared to the end of the previous year[4] - The total equity attributable to shareholders reached ¥15,087,741,872.88 in Q3 2023, up from ¥14,214,807,659.39 in Q3 2022, indicating a growth of about 6.1%[14] - The company's total equity increased to ¥12,445,923,026.83, up from ¥11,863,085,321.52 year-over-year[23] Cash Flow - The company reported a net cash flow from operating activities of approximately ¥9.22 billion year-to-date[3] - The company's cash flow from operating activities showed a positive trend, contributing to the overall financial stability and growth outlook for the upcoming quarters[16] - The net cash flow from operating activities for the first three quarters of 2023 is CNY 9,221,825.72, a significant improvement compared to a negative cash flow of CNY -197,657,174.51 in the same period of 2022[19] - Total cash inflow from operating activities reached CNY 37,922,608,912.16, up from CNY 36,220,437,526.36 in the previous year, indicating a growth of approximately 4.7%[19] - The total cash outflow from operating activities was CNY 37,913,387,086.44, compared to CNY 36,418,094,700.87 in 2022, reflecting an increase of about 4.1%[19] Investments and Expenses - Research and development expenses for the first three quarters of 2023 were ¥53,170,617.46, compared to ¥43,854,628.94 in the same period of 2022, representing an increase of approximately 21.2%[15] - The company reported investment income of ¥286,976,822.59 for the first three quarters of 2023, up from ¥217,571,486.98 in the same period of 2022, reflecting a growth of about 32%[15] - The company reported investment income of ¥503,840,167.01, an increase from ¥440,255,186.81 in the previous year[24] Other Financial Metrics - The weighted average return on equity for Q3 2023 was 3.22%, a decrease of 1.03 percentage points year-over-year, while year-to-date it was 9.57%, a decrease of 1.27 percentage points[4] - The company did not conduct an audit for the Q3 2023 financial statements[2] - The company has adopted new accounting standards starting in 2023, which may affect financial reporting[28]